Idexx Laboratories management check

IDXX · Health Care · Health Care Equipment · CEO Jonathan J. Mazelsky

Filings as of

69
Management score, ranked 185th of 487 · 21st of 60 in Health Care3 good · 4 to watch · 0 flaggedStrongest: clean books · Weakest: CEO cost · Best and worst run in Health Care →

The seven checks

  • Watch

    Have owners done well?

    Trailed its chosen peersOwners$135Peers$148

    What $100 became since fiscal 2021

    3943rd
    Detail

    $100 invested at the start of fiscal 2021 grew to $135, against $148 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    9790th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.94 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    1.4% of net income

    $14.6m pay · $1.1bn net income, FY2025

    0.1%1%3%10%
    3841st
    Detail

    $14.6m of reported pay in fiscal 2025, against $1.1bn of net income.

  • Watch

    Do they own the stock?

    Insiders are selling

    6 mo: ▲ $0 bought · ▼ $28.6m sold

    ——
    Detail

    5 insiders sold $28.6m in the last six months and none bought.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 87m2025 · 81m

    Diluted shares −1.8% a year; flagged above +2%

    0%10%20%

    Stock pay 1.4% of revenue

    7264th
    Detail

    Diluted shares changed -1.8% a year over the last three fiscal years. Stock-based pay was 1.4% of revenue in the latest year.

  • Watch

    Is leadership stable?

    11 leadership filings in 3 years

    11 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Jonathan J. Mazelsky

    7046th
    Detail

    CEO in the pay table: Jonathan J. Mazelsky. 11 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 27, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
−$13.8m$9.0m$31.8m$10020212022202320242025$135$148

Pay tied most to organic revenue growth

Other key measuresOrganic revenue growthOperating profitEarnings per share (diluted)ROIC

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Jonathan J. Mazelsky$14.6m$31.8m$3.1m$135$148$1.1bn
2024—$13.0m$2.3m$3.8m$83$129$887.9m
2023—$11.5m$22.7m$3.3m$111$126$845.0m
2022—$9.8m−$13.8m$2.8m$82$124$679.1m
2021—$9.1m$28.2m$2.8m$132$126$744.8m

Insiders and the CEO's stakeSelling

5 insiders sold $28.6m in the last six months and none bought.

Open-market trades by officers and directors since May 21, 2026.

  • SoldJonathan Jay MazelskyExecutive Chair of the Board$17.7mNov 4, 2026
  • SoldSharon E. UnderbergEVP, GC & Corporate Secretary$6.1mNov 4, 2026
  • SoldMichael LaneExecutive Vice President$2.7mNov 4, 2026
  • SoldLawrence D KingsleyDirector$1.2mSep 4, 2026

Leadership and governance on file

20222023202420252026Leadership 12Votes 5
All 12 filings

Latest shareholder vote results: May 15, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $3.7bn returned to owners in buybacks and dividends, 88% of net income, and $267.6m of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$608.5m$1.2bn20212022202320242025Shares87m85m84m83m81m
Show the figures
Fiscal year20212022202320242025
Revenue$3.2bn$3.4bn$3.7bn$3.9bn$4.3bn
Net income$744.8m$679.1m$845.0m$887.9m$1.1bn
Stock-based pay$37.8m$49.8m$59.7m$60.3m$60.0m
Buybacks$746.8m$819.7m$71.9m$837.0m$1.2bn
Dividends—————
Diluted shares87m85m84m83m81m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.